Sanofi, Regeneron cut Praluent list price by 60%

Sanofi (Euronext:SAN; NASDAQ:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are dropping the list price of PCSK9 inhibitor Praluent alirocumab by 60% to match the $5,850 annual price of competitor LDL-C lowering drug Repatha evolocumab.

Last year, Sanofi and Regeneron reduced Praluent's net price to $4,500-$8,000 for PBMs that agreed to lower utilization management criteria. The partners said Monday that high co-pays and co-insurance under many Medicare Part D plans have prevented last year's price cuts from benefiting patients. The companies declined to specify whether the new list price matches the net price offered to specific PBMs or plans (see "Pralulent Gains Exclusive Status in Exchange for Lower Net Price")...